Trial Software License Agreement Template

In plain language: Identifies the licensor (software owner) and licensee (prospective customer) as legal entities and states the purpose of the agreement — a non-commercial evaluation of the software.

Common mistake: Using a trade name or product brand instead of the licensor's registered legal entity. If a dispute arises, enforcing IP restrictions against the correct rights-holder becomes unnecessarily complicated.

In plain language: Specifies exactly what the licensee can do: access the software, install it on a defined number of devices or seats, and use it for internal evaluation only — nothing broader.

Common mistake: Omitting a seat or device count limit. Without one, enterprise prospects may deploy the software organization-wide under a trial license, creating a de facto free production environment.

In plain language: States the exact start and end dates of the trial, or a duration triggered by activation, and confirms that access automatically terminates at expiry unless converted to a paid license.

Common mistake: Leaving the end date open-ended or subject to mutual written agreement. Vague expiry terms allow trials to extend indefinitely, undermining revenue conversion and creating ongoing IP exposure.

In plain language: Explicitly lists what the licensee may and may not do — prohibiting production use, sublicensing, reverse engineering, benchmarking disclosure, and any commercial exploitation of the software.

Common mistake: Forgetting to prohibit benchmark disclosure. Prospective customers sometimes publish performance comparisons using trial builds — without a restriction, the licensor has no contractual basis to stop them.

In plain language: Confirms that the licensor retains all ownership of the software, documentation, and any modifications, and that the trial grant creates no implied license or ownership rights.

Common mistake: Relying solely on copyright notice rather than an explicit IP reservation clause. Courts in several jurisdictions recognize implied licenses from conduct — a written reservation eliminates that risk.

In plain language: Requires the licensee to keep the software, documentation, pricing, and any non-public information disclosed during the trial strictly confidential for a defined period.

Common mistake: Setting the confidentiality survival period to match the trial length — typically 14 to 90 days. Trade secrets and competitive information need protection well beyond the evaluation window, typically two to five years.

In plain language: Allocates responsibility for any personal or business data entered into the software during the trial, including how it is stored, who owns it, and what happens to it at expiry.

Common mistake: No data handling clause at all. If a prospect enters real production data into a trial environment and the licensor retains it after expiry, GDPR, CCPA, and similar frameworks impose significant penalties on both parties.

In plain language: States clearly that trial software is provided without warranties of any kind — no guarantee of fitness, accuracy, security, or uninterrupted access — limiting the licensor's exposure for bugs or downtime.

Common mistake: Including a limited warranty for the trial period that mirrors the paid product's SLA. This contradicts the 'as is' disclaimer and may create implied support obligations the licensor cannot practically meet for free trials.

In plain language: Caps the total damages either party may recover under the agreement — typically at zero or a nominal amount, reflecting the no-cost nature of the trial.

Common mistake: Carrying over the paid license's liability cap (e.g., 12 months of fees) into the trial agreement. Since trial fees are zero, the cap should be explicitly nominal — otherwise the formula produces a meaningless result.

In plain language: Describes how either party may terminate early, what obligations survive termination, and the conditions under which the trial converts to a paid commercial license.

Common mistake: No conversion clause at all. Without one, a paying customer who used a trial technically has no contractual basis for continued use after the expiry date — even if they have paid — until a new agreement is fully executed.

A trial software license agreement is a legally binding contract between a software licensor and a prospective customer that grants limited, temporary rights to access and evaluate the software before a purchase decision. It defines the scope of permitted use, the evaluation period, IP ownership, confidentiality obligations, and what happens when the trial ends — protecting both parties during the pre-commercial phase of the relationship.

Yes, when properly executed — either by wet signature, e-signature, or a legally compliant clickwrap mechanism — a trial software license agreement is generally enforceable as a binding contract. Courts in the US, UK, and EU have consistently upheld well-drafted trial license terms, including IP restrictions, confidentiality obligations, and disclaimer clauses. Enforceability depends on proper execution before access is granted and on terms being reasonably specific rather than one-sided boilerplate.

A trial license is time-limited and scoped to evaluation use only — it expires automatically and cannot be used for production or commercial purposes. A free (freemium) license is typically perpetual, covers ongoing limited use, and is governed by a standard commercial license agreement with feature restrictions rather than a time constraint. A trial agreement is the right document for a time-bounded evaluation; a software license agreement is the right document for a perpetual free tier.

Yes, and this is one of its primary functions. An explicit IP reservation clause confirms the licensor retains all rights not expressly granted, prohibitions on reverse engineering prevent code extraction, and confidentiality obligations prevent disclosure of technical architecture or trade secrets encountered during the evaluation. Without a signed agreement, the licensor may have only copyright law — and no contractual basis — to enforce these protections against a prospect.

A wet or e-signature is ideal, but for self-serve trials, a clickwrap agreement — where the user actively checks a box or clicks a clearly labeled 'I accept' button before accessing the software — is generally enforceable in the US, UK, and EU. Browse-wrap agreements, where terms are linked in a footer without any active acceptance step, are much harder to enforce and should be avoided. Courts consistently distinguish between active acceptance (enforceable) and passive notice (frequently not).

Trial periods typically run 14 to 30 days for self-serve SaaS products and 30 to 90 days for enterprise pilots requiring procurement approval, security review, and integration testing. The right length depends on your product's complexity and the buyer's decision cycle. Whatever duration you choose, state it as a specific number of days in the contract and build in automatic expiry — open-ended trials consistently convert at lower rates than time-bounded ones.

The trial agreement should specify exactly what happens: typically, the licensee's data is deleted within 30 days of expiry unless the licensee requests an export in writing before that deadline. For trials involving EU or UK data subjects, GDPR and UK GDPR impose specific deletion and portability obligations regardless of what the contract says — the agreement should reference your privacy policy and any data processing addendum to ensure consistency.

Yes — a conversion clause can provide that the trial automatically rolls into a paid subscription on expiry unless the licensee cancels in writing before a defined date. This is common for SaaS products and requires advance notice to the licensee, typically 7 to 14 days before expiry, to be enforceable in consumer-facing contexts. For B2B agreements, automatic conversion with clear advance notice is generally enforceable, but consider the jurisdiction's requirements — some EU member states require explicit opt-in for automatic renewals even in B2B contexts.

For straightforward SaaS trials involving a single jurisdiction and standard evaluation terms, a high-quality template is typically sufficient for most small to mid-size software vendors. Legal review is strongly recommended when the trial involves regulated industries (healthcare, financial services, government), enterprise prospects with significant negotiating power, cross-border data transfers subject to GDPR or other frameworks, or software containing patentable methods or sensitive trade secrets.

A non-disclosure agreement restricts disclosure of confidential information but does not grant any rights to access or use the software itself. A trial license agreement grants limited access rights and typically includes confidentiality obligations as one of its clauses. In practice, many enterprise software evaluations require both documents — an NDA signed before any product demonstrations or technical disclosures, followed by a trial license agreement executed before hands-on access is granted.